Relationship Between FGF19 Overexpression and Disease Prognosis

Launched by BEIJING TSINGHUA CHANG GUNG HOSPITAL · Apr 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between a protein called FGF19 and its impact on the outcomes of patients with advanced liver cancer, known as hepatocellular carcinoma (HCC). Researchers want to find out if higher levels of FGF19 can help predict how well patients will do with their treatment. The study is not yet recruiting participants, but it will focus on adults aged 18 and older who have been diagnosed with intermediate to advanced HCC and have enough tissue samples from previous treatments.

To be eligible for this trial, participants need to have a confirmed diagnosis of liver cancer and expect to live for at least three more months. However, individuals with certain types of rare liver cancers or other health issues that might complicate the trial may not be able to join. Participants will have the opportunity to contribute to important research that could improve understanding and treatment of advanced liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years on the day of signing the informed consent form
• • Histologically or clinically confirmed diagnosis of intermediate to advanced HCC
• • Adequate tissue samples of previous liver cancer
• • Expected survival of more than 3 months
• Exclusion Criteria:
• • Fibrous laminae or sarcomatoid HCC or mixed HCC-ICC, or other rare non-HCC pathologic subtypes
• • Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate